Ozanimod Hydrochloride Patent Expiration
Ozanimod Hydrochloride is Used for treating ulcerative colitis and multiple sclerosis in adults. It was first introduced by Bristol Myers Squibb Co
Ozanimod Hydrochloride Patents
Given below is the list of patents protecting Ozanimod Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zeposia | US11680050 | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof | Sep 30, 2038 | Bristol |
| Zeposia | US8481573 | Modulators of sphingosine phosphate receptors | Mar 24, 2033 | Bristol |
| Zeposia | US10239846 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | Nov 15, 2030 | Bristol |
| Zeposia | US8796318 | Modulators of sphingosine phosphate receptors | May 14, 2029 | Bristol |
| Zeposia | US9382217 | Modulators of sphingosine phosphate receptors | May 14, 2029 | Bristol |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Ozanimod Hydrochloride's patents.
Latest Legal Activities on Ozanimod Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Ozanimod Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate | 04 Mar, 2025 | US8481573 |
| Election in Response to Notice of Final Determination | 26 Feb, 2025 | US8481573 |
| Notice of Final Determination -Eligible | 31 Jan, 2025 | US8481573 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Dec, 2024 | US8481573 |
| FDA Final Eligibility Letter | 18 Dec, 2024 | US8481573 |
| Application ready for PDX access by participating foreign offices | 28 May, 2024 | US8796318 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Dec, 2023 | US9382217 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8481573 |
| transaction for FDA Determination of Regulatory Review Period | 28 Nov, 2023 | US8481573 |
| Recordation of Patent Grant Mailed Critical
| 20 Jun, 2023 | US11680050 |
Ozanimod Hydrochloride's Family Patents
